EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS GAITHERSBURG, Md., February 26, 2026—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2025. "Emergent's 2025 results demonstrate significant progress executing our multi-year turnaround strategy, delivering improved operating margins, strong adjusted EBITDA of $205 million, increased cash flow and lower leverage," said Joe Papa, president and CEO of Emergent. " ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35418 EPAM SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 22-3536104 (State or other jurisdiction of incorporation or organization) 41 University ...

Exhibit 99.1 Organic sales growth in the quarter reflects positive performance from all segments, primarily driven by results of the Infection Prevention and Surgical Solutions business within MedSurg as well as Dental Solutions. GAAP and adjusted operating income margin remained largely consistent with prior year. On an adjusted basis, operating expense savings and the accretive benefit of the Purification and Filtration divestiture more than offset incremental tariff headwinds. Debt paydown following the ...

Exhibit 99.1 Sunrun Reports Fourth Quarter and Full Year 2025 Financial Results Net change in cash and restricted cash of $290 million and Cash Generation of $377 million in 2025 1 Outlook for positive Cash Generation in the range of $250 million to $450 million for full year 2026 2 Aggregate Subscriber Value of $1.3 billion in Q4 Contracted Net Value Creation of $176 million in Q4, or $0.76 per share Storage Attachment Rate reached record 71% in Q4 Paid down $81 million of recourse debt in Q4 with excess c ...

Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook REDWOOD CITY, Calif. February 26, 2026 – Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights "2025 was a challenging year as our customers navigated ongoing budgetary pressures, including uncertainty around NIH funding in the fourth quarter," said Omid ...

Financial Performance - BioLife Solutions, Inc. announced preliminary unaudited revenue for Q4 2025 and the full year ended December 31, 2025[4]. - The report does not provide specific revenue figures or growth percentages in the available content[4]. Compliance and Reporting - The report was filed on January 12, 2026, indicating the company's compliance with the Securities Exchange Act of 1934[4]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[3]. - The financial results will not be deemed "filed" under the Exchange Act, limiting liability under Section 18[5]. - The Chief Financial Officer, Troy Wichterman, signed the report, indicating executive oversight[10]. Company Information - The company is listed on the Nasdaq Stock Market under the trading symbol BLFS[2]. - The company operates from its headquarters located at 3303 Monte Villa Parkway, Bothell, WA[2]. Additional Information - The press release detailing the financial results is attached as Exhibit 99.1[6]. - No information on new products, technologies, market expansion, or mergers and acquisitions was provided in the current report[4].

Revenue and Growth - Revenue for Q4 2025 was $120.9 million, representing a 13% increase compared to Q4 2024[4] - Total revenue for Q4 2025 was $120.887 million, up from $107.090 million in Q4 2024, representing a year-over-year growth of approximately 12.5%[43] - For the full year 2025, total revenue was $457.547 million, compared to $405.908 million in 2024, marking a year-over-year increase of approximately 12.7%[47] - Subscription revenue for Q4 2025 reached $118.504 million, compared to $105.922 million in Q4 2024, indicating a growth of about 11.8%[43] - The approximated TTM subscription revenue contribution for customers contributing $30,000 or more in ARR was $268.0 million, accounting for 59.1% of total subscription revenue[7] Customer Metrics - The number of customers contributing $30,000 or more in ARR grew to 3,803, an increase of 13% compared to the previous year[10] - The number of customers contributing $30,000 or more in ARR is viewed as a key metric for future growth potential[32] - The dollar-based net retention rate was 100% in 2025, down from 104% in 2024[10] - The dollar-based net retention rate was not explicitly stated, but the company emphasizes its importance in evaluating long-term customer relationships[34] Profitability and Income - Non-GAAP operating income was $11.5 million, slightly up from $11.4 million in Q4 2024[4] - Non-GAAP net income was $11.6 million, compared to $10.7 million in Q4 2024[4] - Non-GAAP net income for the twelve months ended December 31, 2025, was $48,237 thousand, compared to $28,633 thousand in 2024, an increase of 68.5%[58] - Non-GAAP net loss per share for Q4 2025 was $0.18, compared to $0.25 in Q4 2024, showing a decrease of 28%[44] Expenses and Losses - The net loss for Q4 2025 was $10.741 million, an improvement from a net loss of $14.417 million in Q4 2024, reflecting a reduction of approximately 25.5%[44] - Total operating expenses for Q4 2025 were $104.573 million, up from $97.354 million in Q4 2024, which is an increase of about 7.5%[44] - Stock-based compensation expense for the full year 2025 totaled $78.719 million, down from $84.303 million in 2024, reflecting a decrease of approximately 6.0%[47] - Stock-based compensation expense for the twelve months ended December 31, 2025, was $78,719 thousand, down from $84,303 thousand in 2024, a decrease of 6.7%[56] Cash and Assets - Cash and cash equivalents totaled $95.3 million as of December 31, 2025, up from $90.6 million as of September 30, 2025[4] - The company reported a net increase in cash, cash equivalents, and restricted cash of $6,785 thousand for the twelve months ended December 31, 2025[56] - Total assets increased to $523,062 thousand in 2025 from $428,341 thousand in 2024, representing a growth of 22.1%[49] - Current assets rose to $237,204 thousand in 2025, up from $210,215 thousand in 2024, an increase of 12.9%[49] - Total stockholders' equity increased to $203,422 thousand in 2025, compared to $166,594 thousand in 2024, reflecting a growth of 22.1%[50] Future Outlook - The company aims for a non-GAAP operating margin of approximately 15% by Q4 2026 and a 30% target for the Rule of 40 framework by Q4 2027[12] - The company expects total revenue for Q1 2026 to be between $119.9 million and $120.7 million[9] Deferred Revenue and Goodwill - Deferred revenue increased to $205,639 thousand in 2025 from $178,585 thousand in 2024, a rise of 15.2%[49] - Goodwill increased significantly to $167,122 thousand in 2025 from $121,315 thousand in 2024, a rise of 37.8%[49]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37622 ______________________ BLOCK, INC. (Exact name of registrant as specified in its chart ...

Exhibit 99.1 Zscaler Announces Strong Second-Quarter Fiscal 2026 Results; Raises Fiscal 2026 ARR Guidance to 24% Exceeds high-end of second-quarter guidance on revenue and profitability metrics Second Quarter Highlights SAN JOSE, California - February 26, 2026 - Zscaler, Inc. (Nasdaq: ZS), the leader in cloud security, today announced financial results for its second quarter of fiscal year 2026, ended January 31, 2026. "We believe Zscaler is the cybersecurity platform for the AI age - our in-line Zero Trust ...

MIAMI, February 26, 2026 – OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: • Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regene ...